Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

NCT05116800 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped IND withdrawn

Conditions

Soft Tissue Sarcoma
Undifferentiated Pleomorphic Sarcoma
Myxofibrosarcoma
Leiomyosarcoma
Liposarcoma
Angiosarcoma
Synovial Sarcoma
Rhabdomyosarcoma
Spindle Cell Sarcoma
High Grade Sarcoma
Bone Sarcoma
Osteosarcoma
Ewing Sarcoma of Bone

Interventions

DRUG: Gemcitabine
DRUG: 9-ING-41
DRUG: Docetaxel

Sponsor

Brown University

Collaborators

[object Object]